{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:30:52Z","timestamp":1782286252566,"version":"3.54.5"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Effective anticancer treatments have dramatically improved the outcome of patients with cancer, but cardiac toxicity reduces their clinical efficacy in a non-negligible percentage of patients. Sacubitril\/valsartan is a new paradigm in the treatment of chronic heart failure, with a reduced ejection fraction due to the enhancement of natriuretic peptides' properties when coupled with a blocking effect on the angiotensin II type 1 (AT1) receptors. As with other clinical conditions of heart failure with potentially reversible declines in cardiac function, a wearable cardioverter defibrillator (WCD) is a valid tool for protection against sudden death until recovery occurs. We report a case series of four patients with chemotherapy-related acute cardiac failure with severely reduced cardiac function. They were successfully treated with sacubitril\/valsartan while being protected from malignant arrhythmias using a wearable cardioverter defibrillator until the recovery of cardiac function. Sacubitril\/valsartan was confirmed to be effective in anthracycline-related cardiac toxicity and the wearable cardioverter defibrillator should be considered as a support tool even in the oncology patient.<\/jats:p>","DOI":"10.3389\/fcvm.2022.801143","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T14:05:02Z","timestamp":1646143502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology"],"prefix":"10.3389","volume":"9","author":[{"given":"Maria Laura","family":"Canale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Coviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Solarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Del Meglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Camerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Maurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Bisceglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Casolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"B1","first-page":"190","article-title":"The prevention of cardiovascular disease in cancer survivors","volume":"39","author":"Daher","year":"2012","journal-title":"Tex Heart Inst J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40959-020-00078-4","article-title":"Use of Sacubitril\/Valsartan in patients with cardio toxicity and heart failure due to chemotherapy","volume":"6","author":"Gregorietti","year":"2020","journal-title":"Cardio-Oncology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ehf2.12627","article-title":"Effectiveness of sacubitril\u2013valsartan in cancer patients with heart failure","volume":"7","author":"Mart\u00edn-Garcia","year":"2020","journal-title":"ESC Heart Fail."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2050313X20952189","DOI":"10.1177\/2050313X20952189","article-title":"A case series about the favorable effects of sacubitril\/valsartan on anthracycline cardiomyopathy","volume":"8","author":"De Vecchis","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1177\/1078155218783238","article-title":"The use of sacubitril\/valsartan in anthracycline-induced cardiomyopathy: a mini case series","volume":"25","author":"Sheppard","year":"2019","journal-title":"J Oncol Pharm Pract."},{"key":"B9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1548-5315(12)70086-4","article-title":"The wearable external cardiac defibrillator for cancer patients at risk for sudden cardiac death","volume":"8","author":"Everitt","year":"2011","journal-title":"Community Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/jmri.26895","article-title":"in cardio-oncology: A review of cardiac complications in oncologic care","volume":"50","author":"Jeong","year":"2019","journal-title":"J Magn Reson Imaging."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/hrt.2005.067355","article-title":"Cardiac magnetic resonance in myocardial disease","volume":"93","author":"Sechtem","year":"2007","journal-title":"Heart."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.21873\/anticanres.13775","article-title":"Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity","volume":"39","author":"Canale","year":"2019","journal-title":"Anticancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40959-020-00083-7","article-title":"In Entresto we trust","volume":"6","author":"Camilli","year":"2020","journal-title":"Cardio-Oncology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.rec.2019.07.006","article-title":"Myocardial function and structure improvement with sacubitril\/valsartan in cancer therapy-induced cardiomyopathy","volume":"73","author":"Mart\u00edn-Garc\u00eda","year":"2020","journal-title":"Rev Esp Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e012272","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jaccao.2020.09.007","article-title":"Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril\/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity","volume":"2","author":"Boutagy","year":"2020","journal-title":"JACC CardioOncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1007\/s12350-018-1293-9","article-title":"Cardiac MRI for the evaluation of oncologic cardiotoxicity","volume":"25","author":"L\u00f6ffler","year":"2018","journal-title":"J Nucl Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"109158","DOI":"10.1016\/j.ejrad.2020.109158","article-title":"Early diagnosis of chemotherapy-induced cardiotoxicity by cardiac MRI","volume":"130","author":"Cau","year":"2020","journal-title":"Eur J Radiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jcmg.2015.11.005","article-title":"T1 Mapping: Basic Techniques and Clinical Applications","volume":"9","author":"Taylor","year":"2016","journal-title":"JACC Cardiovasc Imaging."},{"key":"B20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.carpath.2009.07.004","article-title":"Pathology of late-onset anthracycline cardiomyopathy","volume":"19","author":"Bernaba","year":"2010","journal-title":"Cardiovasc Pathol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1532-429X-15-48","article-title":"Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling","volume":"15","author":"Tham","year":"2013","journal-title":"J Cardiovasc Magn Reson."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/eurheartj\/ehr481","article-title":"Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology","volume":"33","author":"Ugander","year":"2012","journal-title":"Eur Heart J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2018.10.023","article-title":"CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping","volume":"275","author":"Haslbauer","year":"2019","journal-title":"Int J Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00508-018-1411-3","article-title":"A. Comparison of native myocardial T1 and T2 mapping at 15T and 3T in healthy volunteers : Reference values and clinical implications.","volume":"131","author":"Granitz","year":"2019","journal-title":"Wien Klin Wochenschr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJMoa1800781","article-title":"Wearable Cardioverter-Defibrillator after Myocardial Infarction","volume":"379","author":"Olgin","year":"2018","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/jcm9030893","article-title":"The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up","volume":"9","author":"Rosenkaimer","year":"2020","journal-title":"J Clin Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.115.015677","article-title":"Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry)","volume":"132","author":"Kutyifa","year":"2015","journal-title":"Circulation."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.801143\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T14:05:05Z","timestamp":1646143505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.801143\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2022.801143"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.801143","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"article-number":"801143"}}